Business

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and

articleJaguar Health, Inc.January 8, 20253/company/jaguar-animal-health-inc/news/jaguar-health-presenting-january-13-at-lytham-2025-investor-healthcare-summit-and-january-14-at-biotech-showcase
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

About this update from Jaguar Health, Inc.

[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat on January 13, 2025 at the Lytham Partners 2025 Investor Healthcare Summit and in person on January 14, 2025 at Biotech Showcase.Participation Instructions for Jaguar Health's Virtual Fireside Chat at the Lytham Partners 2025 Investor Healthcare SummitWhen: Monday, January 13, 2025 at 12:00 PM Eastern Standard TimeWhere: Online (Click Here). A replay of the webcast will be available through the same link.Participation Instructions for Jaguar Health's In-Person Presentation at Biotech ShowcaseWhen: Tuesday, January 14, 2025 at 3:00 PM Pacific Standard Time; Track: Yosemite AWhere: Hilton San Francisco - Union Square, 333 O'Farrell Street, Ballroom Level, San Francisco, CARegistration link for conference: Click HereAbout the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.For more information about:Jaguar Health, visit https://jaguar.heal...

More updates from Jaguar Health, Inc.